Q-omics provides the consensus-scored TRAF3IP3 profile across patient tissues and cancer cell-line models. TRAF3IP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAF3IP3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TRAF3IP3 protein abundance shows 23,031 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TRAF3IP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAF3IP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAF3IP3 survival associations across molecular data types. TRAF3IP3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAF3IP3 RNA expression–survival associations across cancer types. High TRAF3IP3 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAF3IP3 RNA expression.
This table summarizes TRAF3IP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRAF3IP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAF3IP3 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, HNSC, STAD and BRCA. The KIRC box plot shows higher TRAF3IP3 RNA expression in tumor versus normal tissue (log2 FC = +1.271, t-test p < 0.001).
This table shows molecular features associated with TRAF3IP3 in patient tissues and cancer cell lines. In patient samples, TRAF3IP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAF3IP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
